Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering

Rhea-AI Summary

Vogenx (NASDAQ: VOGX), a clinical-stage biopharmaceutical company targeting diseases linked to metabolic dysfunction, completed an initial public offering of $81.3 million. The IPO comprised 6,250,000 shares of common stock at $13.00 per share, the high end of the proposed range, with all shares sold by Vogenx.

Gross proceeds to Vogenx were approximately $81.3 million before underwriting discounts, commissions, and expenses. Vogenx shares began trading on the Nasdaq Capital Market under the ticker “VOGX” on August 12, 2026, and the offering closed on August 13, 2026. JonesTrading served as sole book-running manager.

Positive

• $81.3 million gross IPO proceeds to Vogenx before costs
• IPO priced at the $13.00 high end of the proposed range
• 6,250,000 primary shares issued, providing new capital to Vogenx
• Vogenx listed on Nasdaq Capital Market under ticker VOGX
• Sole book-running manager mandate completed by JonesTrading, indicating execution capability

Negative

• Net proceeds will be lower than $81.3 million after underwriting discounts, commissions, and other offering expenses

Market reaction after Initial public offering: VOGX +9.37%

+9.37% $16.16

15m delay

+9.37% Vs previous close

$16.16 Last Price

$14.70 $17.00 Day Range

$224.78M Market Cap

0.1x Rel. Volume

Following this news, VOGX has gained 9.37%, reflecting a notable positive market reaction. Our momentum scanner has triggered 6 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $16.16.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

A prior IPO-related announcement was followed by a 4.9% 24-hour move, giving this financing-manager ...

Analysis

A prior IPO-related announcement was followed by a 4.9% 24-hour move, giving this financing-manager release one directly comparable historical reference. Because only one tag-specific event was supplied, the platform record offers limited context for assessing this announcement.

Key Figures

Offering Size: $81.3 million Shares Offered: 6,250,000 shares Public Offering Price: $13.00 per share +3 more

6 metrics

Offering Size $81.3 million Initial public offering

Shares Offered 6,250,000 shares Vogenx common stock

Public Offering Price $13.00 per share At the high end of the proposed range

Gross Proceeds $81.3 million Before underwriting discounts, commissions, and other offering expenses

Nasdaq Trading Start August 12, 2026 Common stock began trading under VOGX

Offering Closing August 13, 2026 Initial public offering

Previous IPO,offering Reports

1 past event · Latest: Aug 13 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 13	Initial public offering	Positive	+4.9%	Closed $81.3 million IPO at $13.00 per share, with shares trading on Nasdaq.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The tag-specific IPO history showed a positive 4.9% 24-hour reaction to the prior closing announcement, but the record contains only one comparable event.

Key Terms

book-running manager, underwriting discounts and commissions

2 terms

book-running manager financial

"served as sole book-running manager for the $81.3 million initial public offering"

A book-running manager is the lead organizer responsible for coordinating a large financial sale, such as issuing new stocks or bonds. They oversee preparing all necessary documents, setting the sale’s price, and finding buyers, much like a concert promoter arranging a major event. Their role matters to investors because they help ensure the offering is successfully sold at the best possible terms.

underwriting discounts and commissions financial

"before deducting underwriting discounts and commissions and other offering expenses"

Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ANGELES and NEW YORK, Aug. 17, 2026 /PRNewswire/ -- JonesTrading Institutional Services LLC ("Jones") today announced that it served as sole book-running manager for the $81.3 million initial public offering of Vogenx, Inc. (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism.

The offering consisted of 6,250,000 shares of Vogenx common stock at a public offering price of $13.00 per share, at the high end of the proposed range. All shares were offered by Vogenx. Gross proceeds to Vogenx from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $81.3 million.

Vogenx's common stock began trading on the Nasdaq Capital Market on August 12, 2026 under the ticker symbol "VOGX." The offering closed on August 13, 2026.

"We are proud to have partnered with Vogenx on this important milestone. This transaction reflects the continued growth of our investment banking and capital markets platform and our ability to deliver thoughtful, high-quality execution for innovative healthcare companies accessing the public markets," said Alan Hill, CEO of JonesTrading.

"The success of this offering underscores the strength of Jones's relationships across the fundamental biotech investment community," said Moe Cohen, Head of Investment Banking at Jones. "Our ability to connect compelling companies with sophisticated, long-term healthcare investors was an important component of the transaction, and we are pleased to support Vogenx as it begins its next chapter as a public company."

"This transaction is a milestone that represents years of hard work from a dedicated team," said Vogenx CEO James Green. "We are now well-capitalized to further the development of therapeutics for the treatment of diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. We are grateful to the Jones team for their partnership, commitment and execution throughout this process, and for helping us reach this important milestone."

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Jones

JonesTrading Institutional Services, LLC ("Jones") is a leading full-service investment banking firm, providing a comprehensive suite of services, including capital markets, M&A, and strategic advisory to corporate clients. The firm is dedicated to building lasting partnerships by delivering innovative solutions, deep industry expertise, and tailored strategies that drive value and success. Founded in 1975, JonesTrading has established itself as the global leader in block trading and a premier liquidity provider to institutional investors. The firm's offerings also include derivatives trading, outsourced trading, electronic trading, prime services, private markets trading, and research/market intelligence. Member FINRA and SIPC.

For more information, please visit www.jonestrading.com

Megan Bracero
mbracero@jonestrading.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/jones-served-as-sole-book-running-manager-for-vogenxs-81-3-million-initial-public-offering-302853039.html

SOURCE JonesTrading Institutional Services

FAQ

How much did Vogenx (NASDAQ: VOGX) raise in its August 2026 IPO?

Vogenx raised gross proceeds of approximately $81.3 million in its IPO. According to JonesTrading, this came from selling 6,250,000 shares of common stock at $13.00 per share, before underwriting discounts, commissions, and other offering expenses.

What was the IPO price and share count for Vogenx (VOGX)?

Vogenx priced its IPO at $13.00 per share for 6,250,000 shares of common stock. According to JonesTrading, the price was at the high end of the proposed range, with all shares offered by Vogenx itself, generating $81.3 million in gross proceeds.

When did Vogenx (VOGX) start trading on Nasdaq and when did the IPO close?

Vogenx common stock began trading on the Nasdaq Capital Market on August 12, 2026. According to JonesTrading, the initial public offering closed on August 13, 2026, following completion of the book-building and allocation process for the 6,250,000 offered shares.

What does the Vogenx (VOGX) IPO mean for its drug development programs?

The IPO provides Vogenx with additional capital to advance its metabolic disease therapeutics. According to Vogenx, it is now well-capitalized to further develop treatments for conditions involving metabolic dysfunction, including post-bariatric hypoglycemia (PBH) and gastroparesis, following this $81.3 million offering.

Who managed the Vogenx (NASDAQ: VOGX) initial public offering?

JonesTrading Institutional Services served as the sole book-running manager for the Vogenx IPO. According to JonesTrading, the transaction highlights its investment banking and capital markets capabilities and its relationships with fundamental biotech investors backing innovative healthcare companies entering the public markets.

Were all Vogenx (VOGX) IPO shares primary shares offered by the company?

Yes, all 6,250,000 shares in the Vogenx IPO were offered by the company itself. According to JonesTrading, the entire $81.3 million in gross proceeds, before costs, went to Vogenx rather than to selling shareholders or secondary holders.